September 5, 2024

Uncategorized

New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: In combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test: CADTH Reimbursement Recommendation [Internet].​Pembrolizumab (Keytruda): Indication: In combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma, whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test: CADTH Reimbursement Recommendation [Internet].

CADTH recommends that Keytruda should be reimbursed by public drug plans for the treatment of locally advanced unresectable or metastatic

Uncategorized

New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: In combination with gemcitabine-based chemotherapy for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma: CADTH Reimbursement Recommendation [Internet].​Pembrolizumab (Keytruda): Indication: In combination with gemcitabine-based chemotherapy for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma: CADTH Reimbursement Recommendation [Internet].

CADTH recommends that public drug plans reimburse Keytruda for the treatment of locally advanced unresectable or metastatic biliary tract carcinoma

Scroll to Top